Spots Global Cancer Trial Database for fallopian tube high grade serous adenocarcinoma

Every month we try and update this database with for fallopian tube high grade serous adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02839707	Fallopian Tube ... Ovarian High Gr... Ovarian Seromuc... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Plati... Recurrent Plati... Recurrent Plati... Recurrent Prima... Recurrent Prima... Recurrent Prima... Recurrent Prima...	Atezolizumab Bevacizumab Computed Tomogr... Pegylated Lipos... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer	NCT04092270	Endometrial Hig... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... FIGO Grade 1 En... FIGO Grade 2 En... Ovarian High Gr... Ovarian Seromuc... Ovarian Undiffe... Platinum-Sensit... Primary Periton... Primary Periton... Primary Periton... Primary Periton... Recurrent Fallo... Recurrent Low G... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Pegylated Lipos... Peposertib	18 Years -	National Cancer Institute (NCI)
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT02659241	Advanced Fallop... Advanced Ovaria... Advanced Primar... Carcinomatosis Fallopian Tube ... Ovarian High Gr... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Adavosertib Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	NCT04616534	Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine	18 Years -	National Cancer Institute (NCI)
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer	NCT05276973	Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Primary Periton... Primary Periton... Stage III Fallo... Stage III Ovari... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Unresectable Fa... Unresectable Fa... Unresectable Ov... Unresectable Ov... Unresectable Pr... Unresectable Pr...	Biopsy Carboplatin Ipatasertib Paclitaxel	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	NCT04616534	Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors	NCT04616534	Advanced Fallop... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Primar... Fallopian Tube ... Metastatic Panc... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton... Stage II Pancre... Stage III Fallo... Stage III Ovari... Stage III Pancr... Stage III Prima... Stage IV Fallop... Stage IV Ovaria... Stage IV Pancre... Stage IV Primar... Unresectable Pa...	Biopsy Biospecimen Col... Diagnostic Imag... Elimusertib Gemcitabine	18 Years -	National Cancer Institute (NCI)
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	NCT04034927	Fallopian Tube ... Fallopian Tube ... Malignant Ovari... Ovarian High Gr... Platinum-Sensit... Platinum-Sensit... Platinum-Sensit... Primary Periton... Recurrent Fallo... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Recurrent Prima...	Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Tremelimumab	18 Years -	National Cancer Institute (NCI)
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	NCT03587311	Fallopian Tube ... Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Platinum-Resist... Platinum-Resist... Platinum-Resist... Primary Periton...	Anetumab Ravtan... Bevacizumab Paclitaxel	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: